Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Clinical trial NCT01439282 · COMPLETED
Trial details
- NCT number
- NCT01439282
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-08-01
- Primary completion
- 2012-11-01
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.